Your Cart

Imagion Biosystems Identifies Key Operational Objectives

Imagion Biosystems Identifies Key Operational Objectives

Imagion Biosystems Limited (Imagion, ASX:IBX), is pleased to provide shareholders and interested parties an outline of its operational objectives as it moves toward first-in-human testing after the completion of its $12 million IPO and subsequent ASX listing.
Read the 12 July 2017 ASX Announcement.

Related Articles

1H2023 Half-Year Results

1H2023 Highlights: Achieved enrolment target for Phase I study of MagSense® HER2 breast cancer detection; imaging results corroborated by independent panel of radiologists Announced plan

Read More

Transforming medical imaging for early disease detection

We’re on a mission to make cancer more detectable.